CBD has lower affinity for CB receptors. It acts as an antagonist or partial antagonist at endogenous cannabinoid receptors (both of those CB1 and CB2 receptor types and other G-protein-coupled receptors [GPCRs]) by inhibiting total binding of immediate ligands, and should act generally at allos